Corbus Pharmaceuticals Holdings's quarterly market cap
declined
from Sep. 2025 (€129.11 Mil) to Dec. 2025 (€120.64 Mil) but then
increased
from Dec. 2025 (€120.64 Mil) to Mar. 2026 (€140.14 Mil).
Corbus Pharmaceuticals Holdings's annual market cap
increased
from Dec. 2023 (€13.27 Mil) to Dec. 2024 (€146.15 Mil) but then
declined
from Dec. 2024 (€146.15 Mil) to Dec. 2025 (€120.64 Mil).
Enterprise Value is the theoretical takeover price. It is more comprehensive than market capitalization (market cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash and cash equivalents. Corbus Pharmaceuticals Holdings's Enterprise Value for Today is €27.25 Mil.
Corbus Pharmaceuticals Holdings (STU:3371) Market Cap Explanation
Market cap is not the real price you pay for a company. If you buy the company and become its owner, you become the owner of the cash the company has, and you also assume the companys debt. The real price you pay is the Enterprise Value.
Warren Buffett uses the ratio of total market cap of all public traded companies over GDP to measure if the market is expensive. As of April 2012, the US total market cap is about $14.7 trillion, while the US GDP is about $15 trillion. The market was modestly overvalued.
Corbus Pharmaceuticals Holdings Market Cap Related Terms
Corbus Pharmaceuticals Holdings Market Cap Historical Data
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
STU:3371 vs PRQR, NRXP, CRBU: Market Cap Comparison
For the Biotechnology subindustry, Corbus Pharmaceuticals Holdings's Market Cap, along with its competitors' market caps and Market Cap data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Corbus Pharmaceuticals Holdings Market Cap vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Corbus Pharmaceuticals Holdings's Market Cap distribution charts can be found below:
* The bar in red indicates where Corbus Pharmaceuticals Holdings's Market Cap falls into.
Corbus Pharmaceuticals Holdings Market Cap Calculation
Market cap is the short version of market capitalization. It is the total market value to buy the whole company. It is equal to the share price times the number of shares outstanding.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Corbus Pharmaceuticals Holdings (STU:3371) has a Market Cap of €147.57 Mil as of Jul. 02, 2026. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Corbus Pharmaceuticals Holdings and its competitors. According to the industry distribution chart, Corbus Pharmaceuticals Holdings ranks #638 out of 1427 companies in the Biotechnology industry, placing it in the top 44.7%.
Is Corbus Pharmaceuticals Holdings' Market Cap too high?
Corbus Pharmaceuticals Holdings' current Market Cap is €147.57 Mil. Based on the distribution chart, Corbus Pharmaceuticals Holdings ranks #638 out of 1427 companies in the Biotechnology industry, which is above the industry midpoint. Overall, Corbus Pharmaceuticals Holdings has a GF Score™ of 31/100 and is considered Significantly Overvalued, reflecting its overall financial health beyond just this single metric.
How does Corbus Pharmaceuticals Holdings' Market Cap compare to PRQR and NRXP?
According to the Biotechnology industry distribution chart, Corbus Pharmaceuticals Holdings ranks #638 out of 1427 companies for Market Cap. This puts Corbus Pharmaceuticals Holdings in the upper half of its industry. The industry median Market Cap is 119.57. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Market Cap for a Biotechnology company?
The median Market Cap among Biotechnology companies is 119.57, based on 1,427 companies in the industry. Companies in the top quartile (top 25%) have a Market Cap significantly above this median, while those in the bottom quartile fall well below. However, Market Cap should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Market Cap mean?
A high Market Cap can signal that a stock is expensive relative to its fundamentals. Market cap equals the total value of a company's shares: price times shares outstanding. View historical data on Corbus Pharmaceuticals Holdings and its competitors. For the Biotechnology industry, the median Market Cap is 119.57 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Corbus Pharmaceuticals Holdings's current Market Cap is €147.57 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Corbus Pharmaceuticals Holdings stock overvalued right now?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings (STU:3371) is currently considered Significantly Overvalued. The stock's GF Value™ is €0.40, compared to a current price of €8.00 — trading 1898.8% above its estimated fair value. The current Market Cap is €147.57 Mil. Corbus Pharmaceuticals Holdings' overall GF Score™ is 31/100 with 1 warning sign to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Market Cap calculated?
Market Cap is calculated from a company's financial statements. For Corbus Pharmaceuticals Holdings (STU:3371), the current Market Cap is €147.57 Mil as of Jul. 02, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Corbus Pharmaceuticals Holdings (STU:3371) Overvalued in 2026?
Based on GuruFocus' analysis, Corbus Pharmaceuticals Holdings stock appears to be overvalued.
The current stock price of €8.00 is trading 1898.8% above its estimated GF Value™ of €0.40.
GuruFocus considers Corbus Pharmaceuticals Holdings to be Significantly Overvalued.
Key valuation signals for STU:3371:
Market Cap: €147.57 Mil
GF Value™: €0.40 vs. price of €8.00 (1898.8% above fair value)
No single metric tells the full story. See the STU:3371 stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Corbus Pharmaceuticals Holdings Business Description
Corbus Pharmaceuticals Holdings Inc is a clinical stage company focused on new therapies in oncology and obesity and is committed to helping people defeat serious illness by bringing inventive scientific approaches to well-understood biological pathways. The company's development pipeline includes; CRB-701, a next-generation antibody-drug conjugate (ADC) that targets the expression of Nectin-4 on cancer cells to release a cytotoxic payload, CRB-601, an anti-integrin monoclonal antibody that blocks the activation of TGF expressed on cancer cells, and CRB-913 a second-generation peripherally restricted CB1 receptor inverse agonist designed to treat obesity.
31GF Score
Get the complete analysis for STU:3371
Market Cap is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
STU:3371 has been successfully added to your 
